Iron in sickle-cell disease: what have we learned over the years? (Q37820936)

23 August 2017

1 reference

title

Iron in sickle-cell disease: what have we learned over the years? (English)

1 reference

23 August 2017

0 references

3

0 references

author name string

Adlette Inati

series ordinal

1

1 reference

23 August 2017

Evelyne Khoriaty

series ordinal

2

1 reference

23 August 2017

publication date

8 November 2010

1 reference

23 August 2017

published in

Pediatric Blood & Cancer

1 reference

23 August 2017

volume

56

1 reference

23 August 2017

issue

2

1 reference

23 August 2017

page(s)

182-190

1 reference

Managing sickle cell disease

23 August 2017

cites work

1 reference

Bone marrow transplantation in sickle cell anemia

21 January 2018

1 reference

Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia

21 January 2018

1 reference

Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia

21 January 2018

1 reference

The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS).

21 January 2018

1 reference

A pilot study of hydroxyurea to prevent chronic organ damage in young children with sickle cell anemia.

21 January 2018

1 reference

Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment

21 January 2018

1 reference

Sickle cell disease and stroke

21 January 2018

1 reference

Effects of a long-term transfusion regimen on sickle cell-related illnesses

21 January 2018

1 reference

High risk of recurrent stroke after discontinuance of five to twelve years of transfusion therapy in patients with sickle cell disease

21 January 2018

1 reference

Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography

21 January 2018

1 reference

Design of the silent cerebral infarct transfusion (SIT) trial.

21 January 2018

1 reference

Hydroxyurea (HU) for prevention of recurrent stroke in sickle cell anemia (SCA).

21 January 2018

1 reference

Leukoreduction of blood components

21 January 2018

1 reference

Practical management of iron overload.

21 January 2018

1 reference

Mechanisms and regulation of intestinal iron absorption

21 January 2018

1 reference

Forging a field: the golden age of iron biology

21 January 2018

1 reference

Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization

21 January 2018

1 reference

Iron metabolism and toxicity

21 January 2018

1 reference

LPI-labile plasma iron in iron overload

21 January 2018

1 reference

Iron toxicity and chelation therapy

21 January 2018

1 reference

Iron overload adversely affects outcome of allogeneic hematopoietic cell transplantation

21 January 2018

1 reference

Red blood cell transfusion dependence and outcome after allogeneic peripheral blood stem cell transplantation in patients with de novo myelodysplastic syndrome (MDS)

21 January 2018

1 reference

Morbidity and mortality in chronically transfused subjects with thalassemia and sickle cell disease: A report from the multi-center study of iron overload

21 January 2018

1 reference

Survival and disease complications in thalassemia major.

21 January 2018

1 reference

Cardiac abnormalities in children with sickle cell anemia.

21 January 2018

1 reference

Absence of cardiac siderosis by MRI T2* despite transfusion burden, hepatic and serum iron overload in Lebanese patients with sickle cell disease

21 January 2018

1 reference

Iron metabolism and iron chelation in sickle cell disease

21 January 2018

1 reference

Oxidative stress and inflammation in iron-overloaded patients with beta-thalassaemia or sickle cell disease.

21 January 2018

1 reference

Cytokine-mediated regulation of iron transport in human monocytic cells

21 January 2018

1 reference

Mechanisms of iron loading and toxicity.

21 January 2018

1 reference

Disparity in the management of iron overload between patients with sickle cell disease and thalassemia who received transfusions

21 January 2018

1 reference

Effect of ascorbic acid deficiency on serum ferritin concentration in patients with beta-thalassaemia major and iron overload

21 January 2018

1 reference

Progression of iron overload in sickle cell disease

21 January 2018

1 reference

Serum ferritin level changes in children with sickle cell disease on chronic blood transfusion are nonlinear and are associated with iron load and liver injury

21 January 2018

1 reference

MRI R2 and R2* mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients

21 January 2018

1 reference

21 January 2018

The beta-thalassemias

1 reference

Relationship between hepatocellular injury and transfusional iron overload prior to and during iron chelation with desferrioxamine: a study in adult patients with acquired anemias

21 January 2018

1 reference

Hepatic iron concentration and total body iron stores in thalassemia major.

21 January 2018

1 reference

Patterns of hepatic iron distribution in patients with chronically transfused thalassemia and sickle cell disease.

21 January 2018

1 reference

Nontransferrin-bound iron in transfused patients with sickle cell disease.

21 January 2018

1 reference

Sickle cell disease: a clinical and histopathologic study of the liver in living children

21 January 2018

1 reference

Iron overload indices rise linearly with transfusion rate in patients with sickle cell disease

21 January 2018

1 reference

Barriers to adherence of deferoxamine usage in sickle cell disease

21 January 2018

1 reference

Deferiprone as an oral iron chelator in sickle cell disease.

21 January 2018

1 reference

Long-term treatment of transfusional iron overload with the oral iron chelator deferiprone (L1): a Dutch multicenter trial.

21 January 2018

1 reference

A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease.

21 January 2018

1 reference

Efficacy and safety of deferasirox doses of >30 mg/kg per d in patients with transfusion-dependent anaemia and iron overload

21 January 2018

1 reference

Deferasirox pharmacokinetics in patients with adequate versus inadequate response

21 January 2018

1 reference

Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias.

21 January 2018

1 reference

Results of long-term iron-chelating therapy

21 January 2018

1 reference

Patient-reported outcomes of deferasirox (Exjade, ICL670) versus deferoxamine in sickle cell disease patients with transfusional hemosiderosis. Substudy of a randomized open-label phase II trial

21 January 2018

1 reference

Adherence to deferasirox in children and adolescents with sickle cell disease during 1-year of therapy

21 January 2018

1 reference

Improving adherence with deferoxamine regimens for patients receiving chronic transfusion therapy

21 January 2018

1 reference

Correlation of liver iron concentration determined by R2 magnetic resonance imaging with serum ferritin in patients with thalassemia intermedia

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/PBC.22721

1 reference

23 August 2017

1 reference